Spruce Biosciences, INC

Spruce Biosciences reported Q2 2026 results, highlighting progress towards a TA-ERT BLA submission in Q4 2026, initiation of the TrAnsform study, and a $5.5 million strategic investment from patient advocacy groups.

Spruce Biosciences announced the appointment of Dr. Adrian Quartel as its new Chief Medical Officer, effective July 27, 2026.

Spruce Biosciences Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its accounting firm.

Spruce Biosciences reported Q1 2026 financial results, highlighting progress on its TA-ERT program for MPS IIIB, strengthened leadership, and a bolstered cash position extending runway into late 2027.

Spruce Biosciences ended its collaboration with Kaken for tildacerfont in Japan while reporting positive 2025 financials and progressing its lead TA-ERT program for MPS IIIB towards a Q4 2026 BLA submission.

Spruce Biosciences announced positive long-term data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating preserved cognitive and motor outcomes.

Spruce Biosciences, Inc. filed its Form 10-Q for the period ending June 30, 2026, detailing continued net losses and a focus on advancing its TA-ERT therapy for MPS IIIB, while highlighting the need for substantial additional financing.

Spruce Biosciences, Inc. filed its Q1 2026 Form 10-Q, detailing financial results, operational updates, and forward-looking statements, with a net loss of $12.3 million.

Spruce Biosciences reports Q3 2025 financial results, highlighting a strategic pivot to TA-ERT for Sanfilippo Syndrome Type B, FDA Breakthrough Therapy Designation, and a recent $50 million private placement to address liquidity concerns.

Spruce Biosciences reports substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and significant workforce reduction, despite positive clinical data for TA-ERT.

Spruce Biosciences reports Q1 2025 results, highlighting a shift towards tralesinidase alfa (TA-ERT) development for Sanfilippo Syndrome Type B amidst delisting concerns and substantial doubt about its ability to continue as a going concern.

Spruce Biosciences reports a net loss of $8.7 million for Q3 2024, with updates on clinical trials for tildacerfont in CAH, PCOS, and MDD.

Spruce Biosciences reports significant net losses and raises substantial doubt about its ability to continue as a going concern despite advancements in its clinical development programs.

Spruce Biosciences terminates one Phase 2b trial for classic CAH after failing to meet primary endpoints, while another trial and a pediatric study show promise, leading to a strategic shift in focus.

Adrian W Quartel, Chief Medical Officer of Spruce Biosciences, Inc., received 13,000 shares of common stock on July 27, 2026.

Javier B. Szwarcberg, CEO of Spruce Biosciences, Inc., acquired 266 shares of common stock through the company's Employee Stock Purchase Plan.

Douglas Kirk Ways, Interim Chief Medical Officer and Director of Spruce Biosciences, reported significant equity transactions including RSU vesting and stock option repricing.

Spruce Biosciences CEO Javier B. Szwarcberg acquired 4,690 shares of common stock at $4.5305 per share through the company's Employee Stock Purchase Plan.

Spruce Biosciences' President and CFO, Samir M. Gharib, reported the vesting of restricted stock units and subsequent tax-related share withholdings.

Spruce Biosciences CEO Javier Szwarcberg reported RSU vestings and a significant stock option repricing, adjusting exercise prices for certain employee and director options.

Spruce Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Spruce Biosciences, Inc. has received conditional approval from Nasdaq to resume trading on the Nasdaq Capital Market, contingent upon stockholder approval of a reverse stock split to meet minimum bid price requirements by August 5, 2025.

Spruce Biosciences, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include the election of three Class II directors, ratification of its independent auditor, and a significant reverse stock split ranging from 1-for-50 to 1-for-100.

Spruce Biosciences, Inc. has announced a supplement to its proxy statement, delaying its annual meeting to July 22, 2025, and proposing a significant reverse stock split to address its Nasdaq delisting and critical financial viability concerns.

Spruce Biosciences is holding its annual stockholder meeting on June 9, 2025, to vote on director elections, auditor ratification, a potential reverse stock split, and adjournment if necessary.

Spruce Biosciences seeks stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and facilitate future financing.

HealthCap VIII, L.P. has reduced its beneficial ownership in Spruce Biosciences, Inc. to 3.4%, falling below the 5% threshold.

A group of RiverVest Venture funds and associated individuals have filed an amended Schedule 13D, indicating they collectively ceased to beneficially own more than 5% of Spruce Biosciences, Inc.'s common stock as of January 7, 2025.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, disclosing their beneficial ownership of Spruce Biosciences, Inc. common stock.

ADAR1 Capital Management and Daniel Schneeberger have updated their beneficial ownership filing for Spruce Biosciences, Inc., reporting a 2.5% stake as of June 30, 2026.

AWM Investment Company, Inc. has disclosed beneficial ownership of 146,988 shares, representing 5.1% of the outstanding common stock of Spruce Biosciences, Inc.

Integrated Core Strategies, Millennium Management, and Israel A. Englander report a reduction in their beneficial ownership of Spruce Biosciences, Inc. common stock to below 5%.

AIGH Capital Management and affiliated entities now beneficially own 9.1% of Spruce Biosciences' common stock, as disclosed in a Schedule 13G filing.

Alyeska Investment Group, L.P. and affiliates have reported a 4.49% beneficial ownership stake in Spruce Biosciences, Inc. as of March 31, 2026.